Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WEE1 is a nuclear protein kinase that plays a crucial role in cell cycle regulation, specifically at the G2/M checkpoint. It inhibits CDK1/cyclin B complex activity by phosphorylating CDK1 at Tyr15, preventing premature entry into mitosis. WEE1 ensures proper DNA replication and repair before cell division. It is a therapeutic target in cancer, as inhibition can induce mitotic catastrophe, particularly in cells with compromised G1 checkpoints. It also has epigenetic functions.
Inhibition of WEE1 leads to premature mitotic entry and mitotic catastrophe, especially in cells with defective G1 checkpoint mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wee one homolog (WEE1).